Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Pediatric Hodgkin Lymphoma, Version 3.2021. Journal of the National Comprehensive Cancer Network : JNCCN Flerlage, J. E., Hiniker, S. M., Armenian, S., Benya, E. C., Bobbey, A. J., Chang, V., Cooper, S., Coulter, D. W., Cuglievan, B., Hoppe, B. S., Isenalumhe, L., Kelly, K., Kersun, L., Lamble, A. J., Larrier, N. A., Magee, J., Oduro, K., Pacheco, M., Price, A. P., Roberts, K. B., Smith, C. M., Sohani, A. R., Trovillion, E. M., Walling, E., Xavier, A. C., Burns, J. L., Campbell, M. 2021; 19 (6): 733-754

Abstract

Hodgkin lymphoma (HL) is a highly curable form of cancer, and current treatment regimens are focused on improving treatment efficacy while decreasing the risk of late effects of treatment. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for pediatric HL provide recommendations on the workup, diagnostic evaluation, and treatment of classic HL, including principles of pathology, imaging, staging, systemic therapy, and radiation therapy. This portion of the NCCN Guidelines focuses on the management of pediatric classic HL in the upfront and relapsed/refractory settings.

View details for DOI 10.6004/jnccn.2021.0027

View details for PubMedID 34214968